Objective To compare the efficacy and safety between liposome-paclitaxel plus carboplatin and paclitaxel plus carboplatin on epithelial ovarian cancer.
Methods We randomly divided 198 cases of epithelial ovarian cancer who had undertook at least six chemotherapy circles after operation into two groups: the experimental group were treated with liposome-paclitaxel (175mg/m2)+carboplatin AUC5 and the control group were treated with paclitaxel (175mg/m2)+carboplatin AUC5. One cycle of chemotherapy was 21 days. A strict observation in the efficacy and adverse reactions of two groups was started from the second chemotherapy cycle.
Results The total effective rates (CR+PR) in the experimental group and control group were 50.50% vs. 53.60% (P=0.738). There were 22(11.11%) recurrent cases after chemotherapy, among which six patients 6(27.27%) patients in the experimental group and 16(72.72%) patients in the control group (P=0.029). The incidences of allergic reactions, alopecia, nausea, vomiting, diarrhea, leukopenia, thrombocytopenia, hepatic dysfunction in the experimental group were significantly lower than those in the control group (P < 0.05), while there was no significant difference in terms of other adverse reactions (P > 0.05).
Conclusion Compared with paclitaxel plus carboplatin group, the efficacy of liposome-paclitaxel plus carboplatin group is equivalent, the recurrence rate is lower in follow-up period, and the incidence of adverse events is significantly lower, including allergic reactions, bone marrow suppression, gastrointestinal reactions and liver dysfunction.
DownLoad: